AI Article Synopsis

  • The text outlines a detailed synthesis process for largazole, which involves eight steps yielding 19%, and discusses the development of important analogues.
  • The synthesis features key reactions, such as a macrocyclization to create a unique 16-membered depsipeptide and an olefin cross-metathesis to add a thioester.
  • Biological tests reveal that largazole targets histone deacetylases (HDACs), specifically functioning as a class I HDAC inhibitor, with the thiol group identified as the critical pharmacophore for its activity.

Article Abstract

Full details of the concise and convergent synthesis (eight steps, 19% overall yield), its extension to the preparation of a series of key analogues, and the molecular target and pharmacophore of largazole are described. Central to the synthesis of largazole is a macrocyclization reaction for formation of the strained 16-membered depsipeptide core followed by an olefin cross-metathesis reaction for installation of the thioester. The biological evaluation of largazole and its key analogues, including an acetyl analogue, a thiol analogue, and a hydroxyl analogue, suggested that histone deacetylases (HDACs) are molecular targets of largazole and largazole is a class I HDAC inhibitor. In addition, structure-activity relationship (SAR) studies revealed that the thiol group is the pharmacophore of the natural product. Largazole's HDAC inhibitory activity correlates with its antiproliferative activity.

Download full-text PDF

Source
http://dx.doi.org/10.1021/ja8013727DOI Listing

Publication Analysis

Top Keywords

molecular target
8
key analogues
8
largazole
6
total synthesis
4
synthesis molecular
4
target largazole
4
largazole histone
4
histone deacetylase
4
deacetylase inhibitor
4
inhibitor full
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!